Mismatch repair status is a predictive factor of tumour response to 5-fluorouracil and irinotecan chemotherapy in patients with advanced colorectal cancer

Tumor Biology

Volumn 28, Issue 4, 2007, Pages 212-220

  Bendardaf, R ^a,b   Lamlum, H ^a,b   Ristamaki R ^a   Korkeila, E ^a   Syrjanen K ^a   Pyrhonen S ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Advanced colorectal cancer; Chemotherapy; DNA mismatch repair; hMLH1; hMSH2; Metastasis

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; PROTEIN MLH1; PROTEIN MSH2;

ADULT; ARTICLE; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MISMATCH REPAIR; MONOTHERAPY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE;

EID: 34548478836     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000107417     Document Type: Article

References (35)

1. Staib L, Link KH, Blatz A, Beger HG: Surgery of colorectal cancer: surgical morbidity and five- and ten-year results in 2,400 patients - monoinstitutional experience. World J Surg 2002;26:59-66.
2. Young A, Rea D: ABC of colorectal cancer: treatment of advanced disease. BMJ 2000;321:1278-1281.
3. Christopoulou A: Chemotherapy in metastatic colorectal cancer. Tech Coloproctol 2004;8(suppl 1):s43-s46.
4. Cunningham D, Pyrhonen S, James RD, et al: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-1418.
5. Jones AM, Douglas EJ, Halford SE, et al: Array-CGH analysis of microsatellite-stable, near-diploid bowel cancers and comparison with other types of colorectal carcinoma. Oncogene 2005;24:118-129.
6. Sieber OM, Heinimann K, Gorman P, et al: Analysis of chromosomal instability in human colorectal adenomas with two mutational hits at APC. Proc Natl Acad Sci USA 2002;99:16910-16915.
7. Shih IM, Zhou W, Goodman SN, et al: Evidence that genetic instability occurs at an early stage of colorectal tumorigenesis. Cancer Res 2001;61:818-822.
8. Lamlum H, Papadopoulou A, Ilyas M, et al: APC mutations are sufficient for the growth of early colorectal adenomas. Proc Natl Acad Sci USA 2000;97:2225-2228.
9. Mori Y, Yin J, Rashid A, et al: Instabilotyping: comprehensive identification of frameshift mutations caused by coding region microsatellite instability. Cancer Res 2001;61:6046-6049.
10. Haydon AM, Jass JR: Emerging pathways in colorectal-cancer development. Lancet Oncol 2002;3:83-88.
11. Thibodeau SN, French AJ, Cunningham JM, et al: Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. Cancer Res 1998;58:1713-1718.
12. Cunningham JM, Christensen ER, Tester DJ, et al: Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 1998;58:3455-3460.
13. Kane MF, Loda M, Gaida GM, et al: Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997;57:808-811.
14. Lengauer C, Kinzler KW, Vogelstein B: Genetic instabilities in human cancers. Nature 1998;396:643-649.
15. Halford S, Sasieni P, Rowan A, et al: Lowlevel microsatellite instability occurs in most colorectal cancers and is a nonrandomly distributed quantitative trait. Cancer Res 2002;62:53-57.
16. Glimelius B, Ristamaki R, Kjaer M, et al: Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer. Ann Oncol 2002;13:1868-1873.
17. Bendardaf R, Lamlum H, Vihinen P, et al: Low collagenase-1 (MMP-1) and MT1-MMP expression levels are favourable survival markers in advanced colorectal carcinoma. Oncology 2003;65:337-346.
18. Aquilina G, Bignami M: Mismatch repair in correction of replication errors and processing of DNA damage. J Cell Physiol 2001;187:145-154.
19. Muller W, Burgart LJ, Krause-Paulus R, et al: The reliability of immunohistochemistry as a prescreening method for the diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC) - results of an international collaborative study. Fam Cancer 2001;1:87-92.
20. Cawkwell L, Gray S, Murgatroyd H, et al: Choice of management strategy for colorectal cancer based on a diagnostic immunohistochemical test for defective mismatch repair. Gut 1999;45:409-415.
21. Chiaravalli AM, Furlan D, Facco C, et al: Immunohistochemical pattern of hMSH2/hMLH1 in familial and sporadic colorectal, gastric, endometrial and ovarian carcinomas with instability in microsatellite sequences. Virchows Arch 2001;438:39-48.
22. Terdiman JP, Gum JR Jr, Conrad PG, et al: Efficient detection of hereditary nonpolyposis colorectal cancer gene carriers by screening for tumor microsatellite instability before germline genetic testing. Gastroenterology 2001;120:21-30.
23. Stahl J: Mismatch repair proteins and microsatellites hit clinical practice. Adv Anat Pathol 2000;7:85-93.
24. Perrin J, Gouvernet J, Parriaux D, et al: MSH2 and MLH1 immunodetection and the prognosis of colon cancer. Int J Oncol 2001;19:891-895.
25. Shia J, Klimstra DS, Nafa K, et al: Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms. Am J Surg Pathol 2005;29:96-104.
26. Chen WS, Chen JY, Liu JM, et al: Microsatellite instability in sporadic-colon-cancer patients with and without liver metastases. Int J Cancer 1997;74:470-474.
27. Shannon BA, Iacopetta BJ: Methylation of the hMLH1, p16, and MDR1 genes in colorectal carcinoma: associations with clinicopathological features. Cancer Lett 2001;167:91-97.
28. Elsaleh H, Iacopetta B: Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma. Clin Colorectal Cancer 2001;1:104-109.
29. Liang JT, Huang KC, Lai HS, et al: High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection. Int J Cancer 2002;101:519-525.
30. Fallik D, Borrini F, Boige V, et al: Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res 2003;63:5738-5744.
31. Ribic CM, Sargent DJ, Moore MJ, et al: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349:247-257.
32. Rosty C, Chazal M, Etienne MC, et al: Determination of microsatellite instability, p53 and K-RAS mutations in hepatic metastases from patients with colorectal cancer: relationship with response to 5-fluorouracil and survival. Int J Cancer 2001;95:162-167.
33. Hemminki A, Mecklin JP, Jarvinen H, et al: Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 2000;119:921-928.
34. Bendardaf R, Lamlum H, Ristamaki R, et al: Response to chemotherapy (irinotecan plus 5-fluorouracil) in colorectal carcinoma can be predicted by tumour DNA content. Oncology 2004;66:46-52.
35. Sobin LH, Fleming ID: TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997;80:1803-1804.